Although PTP1B (PTPN1) was previously known could dephosphorylate some receptor protein tyrosine kinases, studies showed that inhibition of PTP1B could be a new therapeutic strategy for breast cancer, including triple-negative breast cancer [50, 51]. This evidence concerns the gene PTPN1 and breast cancer.